CRAFT-A Proposed Framework for Decentralized Clinical Trials Participation in Canada.

CRAFT Canada decentralized clinical trials remote trial access remote trial framework remote trial management trial cluster

Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
30 09 2021
Historique:
received: 13 08 2021
revised: 15 09 2021
accepted: 24 09 2021
entrez: 22 10 2021
pubmed: 23 10 2021
medline: 28 10 2021
Statut: epublish

Résumé

Canada's vast geography, and centralized delivery of cancer care and clinical trials create barriers for trial participation for patients in remote and rural settings. The development and implementation of a framework that enables safe and regulatory compliant trial participation through local healthcare providers would benefit Canadian patients, clinicians, trial sponsors and the health care system. To address this issue, representatives of Canada's cancer clinical trial community met to identify key challenges and develop recommendations for remote patient participation in trials. A structured literature review identified remote/rural trial delivery models. A panel of expert stakeholders reviewed the models and participated in a workshop to assess health system readiness, identify needed processes, tools and mechanisms, and develop recommendations for a Canadian framework for decentralized clinical trial conduct. The Canadian Remote Access Framework for clinical Trials (CRAFT) represents a risk-based approach used by site investigators to delegate responsibilities for a given trial to satellite health centres within a hub-and-spoke "trial cluster". The Framework includes specific recommendations to ensure research experience, capacity, regulatory compliance and patient safety. Canada's cancer care and telemedicine systems can be leveraged to enable broader access to clinical trials for patients who are geographically remote from cancer centres. CRAFT's risk-based framework is based on other successful models of remote trial patient management and is in the pilot implementation phase in Canada.

Identifiants

pubmed: 34677247
pii: curroncol28050329
doi: 10.3390/curroncol28050329
pmc: PMC8534531
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

3857-3865

Références

J Oncol Pract. 2016 Apr;12(4):e350-8
pubmed: 27026649
Clin Trials. 2010 Aug;7(4):312-21
pubmed: 20595245
Eur J Cancer Care (Engl). 2018 Mar;27(2):e12587
pubmed: 27726212
Curr Oncol Rep. 2017 Aug;19(8):52
pubmed: 28664469
J Natl Cancer Inst. 2007 Mar 21;99(6):420-2
pubmed: 17374826
JAMA. 2017 Jul 11;318(2):197-198
pubmed: 28586821
Am Soc Clin Oncol Educ Book. 2016;35:185-98
pubmed: 27249699
J Natl Cancer Inst. 2019 Mar 1;111(3):245-255
pubmed: 30856272
Pediatr Blood Cancer. 2018 Apr;65(4):
pubmed: 29271602

Auteurs

Stephen Sundquist (S)

Canadian Cancer Clinical Trials Network, Toronto, ON M5G 0A3, Canada.

Gerald Batist (G)

Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada.

Kathy Brodeur-Robb (K)

C17 Council for Children's Cancer and Blood Disorders, Edmonton, AB T6G 1C9, Canada.

Kathryn Dyck (K)

CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada.

Bernhard J Eigl (BJ)

Division of Medical Oncology, BC Cancer, Vancouver, BC V5Z 4E6, Canada.

David K Lee (DK)

Health Products and Food Branch, Health Canada, Ottawa, ON K1A 0K9, Canada.

Jaqueline Limoges (J)

Ontario Cancer Research Ethics Board, Toronto, ON M5G 0A3, Canada.

Holly Longstaff (H)

Provincial Health Services Authority, Vancouver, BC V6H 4C1, Canada.

Jim Pankovich (J)

Bold Therapeutics Inc., Vancouver, BC V6C 1E1, Canada.

Anna Sadura (A)

Canadian Cancer Trials Group, Queen's University, Kingston, ON K7L 3N6, Canada.

Patrick Sullivan (P)

Team Finn Foundation, Vancouver, BC V7K 1V4, Canada.

Janet E Dancey (JE)

Canadian Cancer Clinical Trials Network, Toronto, ON M5G 0A3, Canada.
Canadian Cancer Trials Group, Queen's University, Kingston, ON K7L 3N6, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH